CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 39 target
Drug / intervention
QL1706drug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Histologically confirmed advanced unresectable esophageal squamous cell carcinoma
  • ✓Clinical stage II-IVa (cT1N2-3M0 or cT2-4bN0-3M0 per AJCC 8th Edition)
  • ✓At least 1 measurable or unmeasurable target lesion per RECIST 1.1
  • ✓Age 18-75 years
Key exclusion· 5
  • ✕Prior history of esophageal cancer surgery
  • ✕History of fistula caused by primary tumor infiltration
  • ✕High risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation
  • ✕Poor nutritional status with ≥10% weight loss in first 2 months of screening without improvement after intervention

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05490719
NCT05490719Phase 2RecruitingUpdate OverdueUpdated 25mo ago · Completion was 21mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

A Single Arm, Phase II Clinical Study of Chemoradiationtherapy Combined With QL1706 (Anti-CTLA-4 and PD-1 Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Tianjin Medical University Cancer Institute and Hospital·interventional·Posted Aug 8, 2022·Updated May 21, 2024

In Brief

A Phase 2 clinical trial evaluating QL1706 for Esophageal Squamous Cell Carcinoma. Currently recruiting, targeting 39 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1 antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2RecruitingOverdue
2023202420252026
First PostedAug 8, 2022
Enrollment StartAug 1, 2022
Primary CompletionSep 1, 2024
Study CompletionSep 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.9 years ago

Interventions

QL1706drug

QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.